Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine in Previously Treated Cutaneous T-Cell Lymphoma
NCT00005982Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2000
- Primary completion
- Jul 2004
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nelarabine in cutaneous T-cell lymphoma (CTCL), sponsored by National Cancer Institute. Started Apr 2000; status: terminated.
02
Drugs
nelarabine
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00005982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005982.